Hamburg, June 2018Â –Â Since the groundbreaking discovery of human induced pluripotent stem cells (hiPSCs) by Shinya Yamanaka in 2006, the use of pluripotent stem cells (PSCs) has expeÂrienced a boom. Due to their extensive in vitro self-renewal properties and their ability to differentiate into many different cell types, PSCs, and especially hiPSCs, offer exciting promises in a wide range of cell appliÂcations including regenerative medicine. [Read more…]
Things To Know About An Autologous Stem Cell Transplant
“Autologous stem cell transplant” can be a mouthful to say. Many people don’t know what it means – let alone what a reliable option it is for defeating blood and bone-borne cancers. It has also demonstrated improvements in progression-free survival (PFS). Many of those who undergo the procedure can drive their cancer into remission or permanently defeat it. [Read more…]
How Exosomes Are Revolutionizing Neuroimmunology with Dr. Stefano Pluchino
I am honored to release this interview with Dr. Stefano Pluchino of the highly regarded Pluchino Lab in Cambridge, UK. Dr. Pluchino received his MD and PhD degrees at the University of Siena, Italy, and additional training at Cambridge University, UK.
Dr. Pluchino is an international expert on neuroimmunology-related applications of exosomes, with his lab exploring modalities by which neural progenitor cells (NPCs) engage in cell-to-cell communication. The focus of the laboratory is to explore cellular and molecular mechanisms regulating to the therapeutic plasticity of stem cells in preclinical models of CNS conditions, including multiple sclerosis (MS), stroke, and spinal cord injury. [Read more…]
Cynata Reports Positive 28-day Data from Cohort B of Phase 1 Trial of CYP-001 in GvHD
MELBOURNE, Australia, June 21, 2018 — Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce positive safety and efficacy data from a day 28 analysis of patients in Cohort B of its Phase 1 clinical trial of CYP-001, the Company’s lead Cymerus™ mesenchymal stem cell (MSC) product candidate, in steroid-resistant acute graft-versus-host disease (GvHD). [Read more…]
RMAT Designations Accelerate: 3 New RMATs in Two Weeks
In the past two week, the U.S. FDA has awarded three new RMAT designations, bringing the total number of awards to 19.
The new RMAT designations were awarded to:
- Nightstar Therapeutics: Gene therapy (NSR-REP1)Â for choroideremia treatment –Â June 14, 2018
- Caladrius Biosciences:Â CD34+ cell therapy (CLBS14)Â for refractory angina –Â June 19, 2018
- Voyager Therapeutics: Gene therapy (VY-AADC ) for Parkinson’s disease – June 22, 2018
- « Previous Page
- 1
- …
- 232
- 233
- 234
- 235
- 236
- …
- 336
- Next Page »